{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:14Z","timestamp":1790730734878,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1124\/jpet.119.262238","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T23:55:12Z","timestamp":1582156512000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome"],"prefix":"10.1016","volume":"373","author":[{"given":"Diane M.","family":"Hargrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarkodi","family":"Alagarsamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Croston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gent","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sueiras-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Wi\u015bniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Wi\u015bniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio D.","family":"Schteingart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre J.-M.","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Dimitriadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.262238_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/jpsu.2000.6861","article-title":"Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2","volume":"35","author":"Alavi","year":"2000","journal-title":"J Pediatr Surg"},{"key":"10.1124\/jpet.119.262238_bib2","doi-asserted-by":"crossref","first-page":"e50630","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn\u2019s disease model","volume":"7","author":"Alters","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.262238_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11010-010-0678-0","article-title":"The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha\/actinomycin D","volume":"350","author":"Arda-Pirincci","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/jpet.119.262238_bib4","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1073\/pnas.211278098","article-title":"Modulation of specific intestinal epithelial progenitors by enteric neurons","volume":"98","author":"Bjerknes","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.119.262238_bib5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1517\/14712598.2013.815721","article-title":"Teduglutide in Crohn\u2019s disease","volume":"13","author":"Blonski","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1124\/jpet.119.262238_bib6","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1097\/01.tp.0000576188.42082.4a","article-title":"Pharmacokinetics and pharmacodynamics of glucagon-like peptide (GLP-2) analogue apraglutide (FE 203799) in adult healthy volunteers: results of a phase I trial","volume":"103","author":"Bolognani","year":"2019","journal-title":"Transplantation"},{"key":"10.1124\/jpet.119.262238_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2184.2004.00320.x","article-title":"Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage","volume":"37","author":"Booth","year":"2004","journal-title":"Cell Prolif"},{"key":"10.1124\/jpet.119.262238_bib8","first-page":"E937","article-title":"Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis","volume":"277","author":"Boushey","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.119.262238_bib9","first-page":"687","article-title":"Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor","volume":"61","author":"Boushey","year":"2001","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.119.262238_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/00365520802538195","article-title":"Glucagon-like peptide-2 increases mesenteric blood flow in humans","volume":"44","author":"Bremholm","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1124\/jpet.119.262238_bib11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cphy.c170055","article-title":"Glucagon-like peptide-2 and the regulation of intestinal growth and function","volume":"8","author":"Brubaker","year":"2018","journal-title":"Compr Physiol"},{"key":"10.1124\/jpet.119.262238_bib12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/ibd.21117","article-title":"Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn\u2019s disease","volume":"16","author":"Buchman","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1124\/jpet.119.262238_bib13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-013-0070-y","article-title":"Teduglutide: a review of its use in the treatment of patients with short bowel syndrome","volume":"73","author":"Burness","year":"2013","journal-title":"Drugs"},{"key":"10.1124\/jpet.119.262238_bib14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/ajcn\/71.6.1603","article-title":"Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?","volume":"71","author":"Burrin","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/jpet.119.262238_bib16","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.119.262238_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nbt0797-673","article-title":"Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV","volume":"15","author":"Drucker","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.119.262238_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2005.11.005","article-title":"GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow [published correction appears in Gastroenterology (2006) 130:1019\u20131021]","volume":"130","author":"Guan","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.262238_bib20","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.262238_bib21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.regpep.2006.08.012","article-title":"Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV","volume":"138","author":"Hansen","year":"2007","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.119.262238_bib22","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans","volume":"85","author":"Hartmann","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.119.262238_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1155\/2008\/590143","article-title":"Congenital short bowel syndrome: a case report and review of the literature","volume":"22","author":"Hasosah","year":"2008","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1124\/jpet.119.262238_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2009.05.051","article-title":"Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36","volume":"137","author":"Hsieh","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.262238_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"10.1124\/jpet.119.262238_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00280-012-1882-2","article-title":"Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine","volume":"70","author":"Kissow","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.119.262238_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0148607108316198","article-title":"Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats","volume":"32","author":"Koopmann","year":"2008","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1124\/jpet.119.262238_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1091-255X(98)80005-X","article-title":"Glucagon-like peptide 2 is a potent growth factor for small intestine and colon","volume":"2","author":"Litvak","year":"1998","journal-title":"J Gastrointest Surg"},{"key":"10.1124\/jpet.119.262238_bib32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/0091270008320605","article-title":"Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects","volume":"48","author":"Marier","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.119.262238_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2005.10.004","article-title":"Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans","volume":"130","author":"Meier","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.262238_bib34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.161497","article-title":"GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus","volume":"333","author":"Moore","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.262238_bib35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1073\/pnas.96.4.1569","article-title":"Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2","volume":"96","author":"Munroe","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.119.262238_bib36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00365520410004424","article-title":"Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1","volume":"39","author":"Nagell","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1124\/jpet.119.262238_bib38","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1210\/en.2006-1232","article-title":"Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat","volume":"148","author":"Nelson","year":"2007","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.262238_bib39","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2174\/092986709789712907","article-title":"The medicinal chemistry of peptides","volume":"16","author":"Nestor","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.119.262238_bib40","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"Orskov","year":"1986","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.262238_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.regpep.2004.07.009","article-title":"GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors","volume":"124","author":"\u00d8rskov","year":"2005","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.119.262238_bib42","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1007\/s10620-009-1104-x","article-title":"The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin","volume":"55","author":"Rasmussen","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1124\/jpet.119.262238_bib43","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00039.2011","article-title":"The \u201ccryptic\u201d mechanism of action of glucagon-like peptide-2","volume":"301","author":"Rowland","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/jpet.119.262238_bib45","doi-asserted-by":"crossref","first-page":"G211","DOI":"10.1152\/ajpgi.00530.2006","article-title":"Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2","volume":"293","author":"Sigalet","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/jpet.119.262238_bib46","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jpen.1500","article-title":"Novel long-acting GLP-2 analogue, FE 203799 (apraglutide), enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum","volume":"43","author":"Slim","year":"2019","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1124\/jpet.119.262238_bib47","doi-asserted-by":"crossref","first-page":"R283","DOI":"10.1152\/ajpregu.00588.2005","article-title":"Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets","volume":"290","author":"Stephens","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.119.262238_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/jsre.2000.5917","article-title":"Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis","volume":"91","author":"Tavakkolizadeh","year":"2000","journal-title":"J Surg Res"},{"key":"10.1124\/jpet.119.262238_bib49","doi-asserted-by":"crossref","first-page":"E134","DOI":"10.1152\/ajpendo.2000.278.1.E134","article-title":"Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats","volume":"278","author":"Tavares","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.262238_bib50","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.ijrobp.2007.08.051","article-title":"Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat","volume":"69","author":"Torres","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1124\/jpet.119.262238_bib51","first-page":"E77","article-title":"Intestinal growth-promoting properties of glucagon-like peptide-2 in mice","volume":"273","author":"Tsai","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.119.262238_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/pgmj.2004.023846","article-title":"Intestinal adaptation after massive intestinal resection","volume":"81","author":"Weale","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1124\/jpet.119.262238_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"key":"10.1124\/jpet.119.262238_bib55","first-page":"1","article-title":"Intestinal growth induced by glucagon-like peptide-2 in a mouse model of gluten sensitivity gastroenterology","volume":"0","author":"Wheeler","year":"2018","journal-title":"GASTROENTEROLOGY"},{"key":"10.1124\/jpet.119.262238_bib57","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1021\/acs.jmedchem.5b01909","article-title":"Synthesis and pharmacological characterization of novel glucagon-like peptide-2 (GLP-2) analogues with low systemic clearance","volume":"59","author":"Wi\u015bniewski","year":"2016","journal-title":"J Med Chem"},{"issue":"7","key":"10.1124\/jpet.119.262238_bib56","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1021\/acs.jmedchem.5b01909","article-title":"Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance","volume":"59","author":"Wi\u015bniewski","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.262238_bib58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0016-5085(99)70555-X","article-title":"Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans","volume":"117","author":"Xiao","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.262238_bib60","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/gast.2000.16489","article-title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","volume":"119","author":"Yusta","year":"2000","journal-title":"Gastroenterology"}],"updated-by":[{"DOI":"10.1124\/jpet.119.262899err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000}},{"DOI":"10.1124\/jpet.119.262238err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000}}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.262238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:56:06Z","timestamp":1739973366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0022356524258717"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.262238","relation":{"erratum":[{"id-type":"doi","id":"10.1124\/jpet.119.262238err","asserted-by":"object"},{"id-type":"doi","id":"10.1124\/jpet.119.262899err","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.262238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}